Exclusive: Mount Sinai tried to stifle debate over revelations about its controversial brain research

The campaign began after a STAT investigation disclosed that an FDA review concluded that Mount Sinai researchers were misleading patients to obtain biopsies

July 31, 2024 Check out STAT+

Sponsored By

Alice Proujansky for STAT STAT+ | Mount Sinai mounted aggressive campaign to stifle debate over revelations about its controversial brain research The hospital network enlisted patients to defend the research and sought to block a statement from a professional group about the research. By Katherine Eban What I learned about ultra-processed foods from stuffing my face at the world's leading food technology event As consumers become more aware of ultra-processed food issues, manufacturers see "opportunities for growth" in more craveable products. By Nicholas Florko Biden administration should push for addiction medication in recovery houses, groups say Advocates say recovery houses' hostility to buprenorphine or methadone treatment flouts the Americans with Disabilities Act. By Lev Facher John Locher/AP STAT+ | 7 key people who could shape Trump's health care policy Top aides and officials who shaped the Trump administration's efforts to cut drug prices and ban surprise medical bills could return. By Sarah Owermohle and Rachel Cohrs Zhang STAT+ | NIH loses suit over censoring social media comments made by animal rights advocates At issue was an effort by the National Institutes of Health to exclude "off-topic" discussions about its work By Ed Silverman STAT+ | Eisai, Biogen make case for long-term use of Alzheimer's drug Leqembi with new data It's unclear if the new data will convince doctors to use Leqembi continuously, or if the treatment's benefit is clinically meaningful for patients. By Elaine Chen and Adam Feuerstein Michael M. Santiago/Getty Images STAT+ | Wells Fargo faces class action lawsuit over workers' high drug costs The lawsuit says that Wells Fargo's workers paid too much for prescription drugs because the company did a poor job overseeing its health benefits. By Bob Herman and Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser